NO20050400L - Nytt kombinasjonspreparat - Google Patents

Nytt kombinasjonspreparat

Info

Publication number
NO20050400L
NO20050400L NO20050400A NO20050400A NO20050400L NO 20050400 L NO20050400 L NO 20050400L NO 20050400 A NO20050400 A NO 20050400A NO 20050400 A NO20050400 A NO 20050400A NO 20050400 L NO20050400 L NO 20050400L
Authority
NO
Norway
Prior art keywords
new combination
combination preparation
pde5
cgmp
angiotensin
Prior art date
Application number
NO20050400A
Other languages
English (en)
Norwegian (no)
Inventor
David Nathan Abraham Fox
Bernadette Hughes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20050400L publication Critical patent/NO20050400L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20050400A 2002-06-26 2005-01-25 Nytt kombinasjonspreparat NO20050400L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0214784.1A GB0214784D0 (en) 2002-06-26 2002-06-26 Novel combination
PCT/IB2003/002657 WO2004002461A2 (fr) 2002-06-26 2003-06-16 Nouvelle combinaison

Publications (1)

Publication Number Publication Date
NO20050400L true NO20050400L (no) 2005-03-29

Family

ID=9939342

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050400A NO20050400L (no) 2002-06-26 2005-01-25 Nytt kombinasjonspreparat

Country Status (20)

Country Link
EP (1) EP1524996A2 (fr)
JP (1) JP2005531627A (fr)
KR (1) KR20050013156A (fr)
CN (1) CN1662257A (fr)
AR (1) AR040337A1 (fr)
AU (1) AU2003242895A1 (fr)
BR (1) BR0312030A (fr)
CA (1) CA2491002A1 (fr)
GB (1) GB0214784D0 (fr)
GT (1) GT200300124A (fr)
MX (1) MXPA04012569A (fr)
NO (1) NO20050400L (fr)
PA (1) PA8575501A1 (fr)
PE (1) PE20040868A1 (fr)
PL (1) PL375079A1 (fr)
RU (1) RU2004136276A (fr)
TW (1) TW200404546A (fr)
UY (1) UY27863A1 (fr)
WO (1) WO2004002461A2 (fr)
ZA (1) ZA200409532B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
JPWO2004036162A1 (ja) * 2002-07-26 2006-02-16 オリンパス株式会社 画像処理システム
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
BRPI0502411A (pt) * 2005-03-31 2006-11-28 Univ Minas Gerais processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados
RU2369392C2 (ru) * 2005-06-10 2009-10-10 Донг-А Фармасьютикал. Ко., Лтд. Средство для профилактики и лечения заболеваний печени, содержащее производное пиразолопиримидинона
WO2007010337A2 (fr) * 2005-07-15 2007-01-25 Proxomed Medizintechnik Gmbh Utilisation d'inhibiteurs de phosphodiesterase type 5 pour la prevention et le traitement de maladies ou de troubles, et systemes d'administration associes
JP2009512711A (ja) * 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
AU2007249399A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
ATE213246T1 (de) * 1997-11-12 2002-02-15 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
BR0014695A (pt) * 1999-10-11 2002-06-18 Pfizer 5-(2-substituìdo-5-heterociclilsulfonilpirid-3-il)-dihi dropirazolo[4,3-d]pirimidin-7-onas como inibidoras de fosfodiesterase
CA2419033A1 (fr) * 2000-08-11 2002-02-21 Earl Michael Gibbs Traitement du syndrome de la resistance a l'insuline

Also Published As

Publication number Publication date
WO2004002461A3 (fr) 2004-05-13
BR0312030A (pt) 2005-03-22
WO2004002461A2 (fr) 2004-01-08
JP2005531627A (ja) 2005-10-20
GB0214784D0 (en) 2002-08-07
PA8575501A1 (es) 2003-12-30
KR20050013156A (ko) 2005-02-02
ZA200409532B (en) 2006-06-28
CN1662257A (zh) 2005-08-31
GT200300124A (es) 2004-03-17
PE20040868A1 (es) 2004-11-25
MXPA04012569A (es) 2005-04-19
EP1524996A2 (fr) 2005-04-27
AR040337A1 (es) 2005-03-30
AU2003242895A1 (en) 2004-01-19
RU2004136276A (ru) 2005-09-10
CA2491002A1 (fr) 2004-01-08
UY27863A1 (es) 2003-12-31
PL375079A1 (en) 2005-11-14
TW200404546A (en) 2004-04-01

Similar Documents

Publication Publication Date Title
NO20050400L (no) Nytt kombinasjonspreparat
CY1105390T1 (el) Θepαπευτικη αγωγη της πνευμονικης υπερτασης
WO2002102314A3 (fr) Inhibiteurs puriques de phosphodiesterase (pde) 7
CY1109219T1 (el) Ινδολο, αζαινδολο και σχετικα ετεροκυκλικα αμιδοπιπεραζινο παραγωγα
DK1443925T3 (da) Naphthyridinderivater, deres fremstilling og deres anvendelse som inhibitorer af phosphodiesteraseisoenzym 4 (PDE4)
AR022665A1 (es) Compuestos farmaceuticamente activos
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
NO20053115L (no) Fremgangsmate for fremstilling av 2'-forgrenede nukleosider.
HN2003000054A (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo (cetpi), a procedimientos de uso y a procedimientos de preparacion de las mismas.
WO2003017936A3 (fr) Utilisation d'inhibiteurs de la dppiv utilises comme agents diuretiques et anti-hypertenseurs
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
NO20061072L (no) Doseringsformer som tilveiebringer kontrollert frigivning av kolesterylesteroverfonngsprotetntnhibttorer og umiddelbar frigivning av HMG-COA-reduktase-Inhibitor
DE60130555D1 (de) 1-(heteroaryl-phenyl)-kondensierte pyrazol-derivate als factor xa inhibitoren
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
CY2012009I1 (el) Αναστολεις της κυκλοπροπυλ-συντηκωμενης διπεπτυλοπεπτιδασης 4, βασισμενοι σε πυρρολιδινη, και μεθοδοι για την παρασκευη των και την χρηση των
YU49315B (sh) Inhibitor protein kinaze c, njegove farmaceutske formulacije i postupak za dobijanje
MXPA05012302A (es) Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5.
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
NO20045517L (no) Ny kombinasjon
NO995657L (no) Kombinasjonsterapi for endring av human seksuell respons
DE60121587D1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
ATE390425T1 (de) Xanthin-phosphodiesterase-v-hemmer polymorphe
NO20071096L (no) Diarylmetylpiperazinderivater, fremstillinger derav og anvendelser derav
ATE531690T1 (de) Inhibitoren von peptiddeformylase

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application